AMPA receptor

From Wikipedia, the free encyclopedia
The AMPA receptor bound to a glutamate antagonist showing the amino terminal, ligand binding, and transmembrane domain, PDB 3KG2

The α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (also known as AMPA receptor, AMPAR, or quisqualate receptor) is an ionotropic transmembrane receptor for glutamate (iGluR) that mediates fast synaptic transmission in the central nervous system (CNS). It has been traditionally classified as a non-NMDA-type receptor, along with the kainate receptor. Its name is derived from its ability to be activated by the artificial glutamate analog AMPA. The receptor was first named the "quisqualate receptor" by Watkins and colleagues after a naturally occurring agonist quisqualate and was only later given the label "AMPA receptor" after the selective agonist developed by Tage Honore and colleagues at the Royal Danish School of Pharmacy in Copenhagen.[1] The GRIA2-encoded AMPA receptor ligand binding core (GluA2 LBD) was the first glutamate receptor ion channel domain to be crystallized.[2]

Structure and function[]

Subunit composition[]

AMPARs are composed of four types of subunits encoded by different genes, designated as GRIA1 (also named GluA1 or GluR1), GRIA2 (also named GluA2 or GluR2), GRIA3 (Also named GluA3 or GluR3), and GRIA4 (also called GluA4 or GluRA-D2 ), which combine to form tetramers.[3][4][5] Most AMPARs are heterotetrameric, consisting of symmetric 'dimer of dimers' of GluA2 and either GluA1, GluA3 or GluA4.[6][7] Dimerization starts in the endoplasmic reticulum with the interaction of N-terminal LIVBP domains, then "zips up" through the ligand-binding domain into the transmembrane ion pore.[7]

The conformation of the subunit protein in the plasma membrane caused controversy for some time. While the amino acid sequence of the subunit indicated that there seemed to be four transmembrane domains (parts of the protein that pass through the plasma membrane), proteins interacting with the subunit indicated that the N-terminus seemed to be extracellular, while the C-terminus seemed to be intracellular. However, if each of the four transmembrane domains went all the way through the plasma membrane, then the two termini would have to be on the same side of the membrane. It was eventually discovered that the second "transmembrane" domain does not in fact cross the membrane at all, but kinks back on itself within the membrane and returns to the intracellular side.[8] When the four subunits of the tetramer come together, this second membranous domain forms the ion-permeable pore of the receptor.

AMPAR subunits differ most in their C-terminal sequence, which determines their interactions with scaffolding proteins. All AMPARs contain PDZ-binding domains, but which PDZ domain they bind to differs. For example, GluA1 binds to SAP97 through SAP97's class I PDZ domain,[9] while GluA2 binds to PICK1[10] and GRIP/ABP. Of note, AMPARs cannot directly bind to the common synaptic protein PSD-95 owing to incompatible PDZ domains, although they do interact with PSD-95 via stargazin (the prototypical member of the TARP family of AMPAR auxiliary subunits).[11]

Phosphorylation of AMPARs can regulate channel localization, conductance, and open probability. GluA1 has four known phosphorylation sites at serine 818 (S818), S831, threonine 840, and S845 (other subunits have similar phosphorylation sites, but GluR1 has been the most extensively studied). S818 is phosphorylated by protein kinase C, and is necessary for long-term potentiation (LTP; for GluA1's role in LTP, see below).[12] S831 is phosphorylated by CaMKII and PKC during LTP, which helps deliver GluA1-containing AMPAR to the synapse,[13] and increases their single channel conductance.[14] The T840 site was more recently discovered, and has been implicated in LTD.[15] Finally, S845 is phosphorylated by PKA which regulates its open probability.[16]

Ion channel function[]

Each AMPAR has four sites to which an agonist (such as glutamate) can bind, one for each subunit.[6] The binding site is believed to be formed by the N-terminal tail and the extracellular loop between transmembrane domains three and four.[17] When an agonist binds, these two loops move towards each other, opening the pore. The channel opens when two sites are occupied,[18] and increases its current as more binding sites are occupied.[19] Once open, the channel may undergo rapid desensitization, stopping the current. The mechanism of desensitization is believed to be due to a small change in angle of one of the parts of the binding site, closing the pore.[20] AMPARs open and close quickly (1ms), and are thus responsible for most of the fast excitatory synaptic transmission in the central nervous system.[18] The AMPAR's permeability to calcium and other cations, such as sodium and potassium, is governed by the GluA2 subunit. If an AMPAR lacks a GluA2 subunit, then it will be permeable to sodium, potassium, and calcium. The presence of a GluA2 subunit will almost always render the channel impermeable to calcium. This is determined by post-transcriptional modification — RNA editing — of the Q-to-R editing site of the GluA2 mRNA. Here, A→I editing alters the uncharged amino acid glutamine (Q) to the positively charged arginine (R) in the receptor's ion channel. The positively charged amino acid at the critical point makes it energetically unfavourable for calcium to enter the cell through the pore. Almost all of the GluA2 subunits in CNS are edited to the GluA2(R) form. This means that the principal ions gated by AMPARs are sodium and potassium, distinguishing AMPARs from NMDA receptors (the other main ionotropic glutamate receptors in the brain), which also permit calcium influx. Both AMPA and NMDA receptors, however, have an equilibrium potential near 0 mV. The prevention of calcium entry into the cell on activation of GluA2-containing AMPARs is proposed to guard against excitotoxicity.[21]

The subunit composition of the AMPAR is also important for the way this receptor is modulated. If an AMPAR lacks GluA2 subunits, then it is susceptible to being blocked in a voltage-dependent manner by a class of molecules called polyamines. Thus, when the neuron is at a depolarized membrane potential, polyamines will block the AMPAR channel more strongly, preventing the flux of potassium ions through the channel pore. GluA2-lacking AMPARs are, thus, said to have an inwardly rectifying I/V curve, which means that they pass less outward current than inward current at equivalent distance from the reversal potential. Calcium permeable AMPARs are found typically early during postnatal development, on some interneurons or in dopamine neurons of the ventral tegmental area after the exposure to an addictive drug.[22]

Alongside RNA editing, alternative splicing allows a range of functional AMPA receptor subunits beyond what is encoded in the genome. In other words, although one gene (GRIA1–GRIA4) is encoded for each subunit (GluA1–GluA4), splicing after transcription from DNA allows some exons to be translated interchangeably, leading to several functionally different subunits from each gene.[23]

The flip/flop sequence is one such interchangeable exon. A 38-amino acid sequence found prior to (i.e., before the N-terminus of) the fourth membranous domain in all four AMPAR subunits, it determines the speed of desensitisation[24] of the receptor and also the speed at which the receptor is resensitised[25] and the rate of channel closing.[26] The flip form is present in prenatal AMPA receptors and gives a sustained current in response to glutamate activation.[27]

Synaptic plasticity[]

AMPA receptors (AMPAR) are both glutamate receptors and cation channels that are integral to plasticity and synaptic transmission at many postsynaptic membranes. One of the most widely and thoroughly investigated forms of plasticity in the nervous system is known as long-term potentiation, or LTP. There are two necessary components of LTP: presynaptic glutamate release and postsynaptic depolarization. Therefore, LTP can be induced experimentally in a paired electrophysiological recording when a presynaptic cell is stimulated to release glutamate on a postsynaptic cell that is depolarized. The typical LTP induction protocol involves a “tetanus” stimulation, which is a 100 Hz stimulation for 1 second. When one applies this protocol to a pair of cells, one will see a sustained increase of the amplitude of the excitatory postsynaptic potential (EPSP) following tetanus. This response is interesting since it is thought to be the physiological correlate for learning and memory in the cell. In fact, it has been shown that, following a single paired-avoidance paradigm in mice, LTP can be recorded in some hippocampal synapses in vivo.[28]

The molecular basis for LTP has been extensively studied, and AMPARs have been shown to play an integral role in the process. Both GluR1 and GluR2 play an important role in synaptic plasticity. It is now known that the underlying physiological correlate for the increase in EPSP size is a postsynaptic upregulation of AMPARs at the membrane,[29] which is accomplished through the interactions of AMPARs with many cellular proteins.

The simplest explanation for LTP is as follows (see the long-term potentiation article for a much more detailed account). Glutamate binds to postsynaptic AMPARs and another glutamate receptor, the NMDA receptor (NMDAR). Ligand binding causes the AMPARs to open, and Na+ flows into the postsynaptic cell, resulting in a depolarization. NMDARs, on the other hand, do not open directly because their pores are occluded at resting membrane potential by Mg2+ ions. NMDARs can open only when a depolarization from the AMPAR activation leads to repulsion of the Mg2+ cation out into the extracellular space, allowing the pore to pass current. Unlike AMPARs, however, NMDARs are permeable to both Na+ and Ca2+. The Ca2+ that enters the cell triggers the upregulation of AMPARs to the membrane, which results in a long-lasting increase in EPSP size underlying LTP. The calcium entry also phosphorylates CaMKII, which phosphorylates AMPARs, increasing their single-channel conductance.

AMPA receptor trafficking[]

Regulation of AMPAR trafficking to the postsynaptic density in response to LTP-inducing stimuli
Regulation of AMPAR trafficking to the postsynaptic density in response to LTP-inducing stimuli

Molecular and signaling response to LTP-inducing stimuli[]

The mechanism for LTP has long been a topic of debate, but, recently, mechanisms have come to some consensus. AMPARs play a key role in this process, as one of the key indicators of LTP induction is the increase in the ratio of AMPAR to NMDARs following high-frequency stimulation. The idea is that AMPARs are trafficked from the dendrite into the synapse and incorporated through some series of signaling cascades.

AMPARs are initially regulated at the transcriptional level at their 5’ promoter regions. There is significant evidence pointing towards the transcriptional control of AMPA receptors in longer-term memory through cAMP response element-binding protein (CREB) and Mitogen-activated protein kinases (MAPK).[30] Messages are translated on the rough endoplasmic reticulum (rough ER) and modified there. Subunit compositions are determined at the time of modification at the rough ER.[10] After post-ER processing in the golgi apparatus, AMPARs are released into the perisynaptic membrane as a reserve waiting for the LTP process to be initiated.

The first key step in the process following glutamate binding to NMDARs is the influx of calcium through the NMDA receptors and the resultant activation of Ca2+/calmodulin-dependent protein kinase (CaMKII).[31] Blocking either this influx or the activation of CaMKII prevents LTP, showing that these are necessary mechanisms for LTP.[32] In addition, profusion of CaMKII into a synapse causes LTP, showing that it is a causal and sufficient mechanism.[33]

CaMKII has multiple modes of activation to cause the incorporation of AMPA receptors into the perisynaptic membrane. CAMKII enzyme is eventually responsible for the development of the actin cytoskeleton of neuronal cells and, eventually, for the dendrite and axon development (synaptic plasticity).[34] The first is direct phosphorylation of synaptic-associated protein 97(SAP97).[35] First, SAP-97 and Myosin-VI, a motor protein, are bound as a complex to the C-terminus of AMPARs. Following phosphorylation by CaMKII, the complex moves into the perisynaptic membrane.[36] The second mode of activation is through the MAPK pathway. CaMKII activates the Ras proteins, which go on to activate p42/44 MAPK, which drives AMPAR insertion directly into the perisynaptic membrane.[37]

AMPA receptor trafficking to the PSD in response to LTP[]

Once AMPA receptors are transported to the perisynaptic region through PKA or SAP97 phosphorylation, receptors are then trafficked to the postsynaptic density (PSD). However, this process of trafficking to the PSD still remains controversial. One possibility is that, during LTP, there is lateral movement of AMPA receptors from perisynpatic sites directly to the PSD.[38] Another possibility is that exocytosis of intracellular vesicles is responsible for AMPA trafficking to the PSD directly.[39] Recent evidence suggests that both of these processes are happening after an LTP stimulus; however, only the lateral movement of AMPA receptors from the perisynaptic region enhances the number of AMPA receptors at the PSD.[40] The exact mechanism responsible for lateral movement of AMPA receptors to the PSD remains to be discovered; however, research has discovered several essential proteins for AMPA receptor trafficking. For example, overexpression of SAP97 leads to increased AMPA receptor trafficking to synapses.[41] In addition to influencing synaptic localization, SAP97 has also been found to influence AMPA receptor conductance in response to glutamate.[42] Myosin proteins are calcium sensitive motor proteins that have also been found to be essential for AMPA receptor trafficking. Disruption of myosin Vb interaction with Rab11 and Rab11-FIP2 blocks spine growth and AMPA receptor trafficking.[43] Therefore, it is possible that myosin may drive the lateral movement of AMPA receptors in the perisynpatic region to the PSD. Transmembrane AMPA receptor regulatory proteins (TARPs) are a family proteins that associate with AMPA receptors and control their trafficking and conductance.[44] CACNG2 (Stargazin) is one such protein and is found to bind AMPA receptors in the perisynaptic and postsynaptic regions.[45] The role of stargazin in trafficking between the perisynaptic and postsynaptic regions remains unclear; however, stargazin is essential for immobilizing AMPA receptors in the PSD by interacting with PSD-95.[46] PSD-95 stabilizes AMPA receptors to the synapse and disruption of the stargazin-PSD-95 interaction suppressed synaptic transmission.[47]

Constitutive trafficking and changes in subunit composition[]

AMPA receptors are continuously being trafficked (endocytosed, recycled, and reinserted) into and out of the plasma membrane. Recycling endosomes within the dendritic spine contain pools of AMPA receptors for such synaptic reinsertion.[48] Two distinct pathways exist for the trafficking of AMPA receptors: a regulated pathway and a constitutive pathway.[49][50]

In the regulated pathway, GluA1-containing AMPA receptors are trafficked to the synapse in an activity-dependent manner, stimulated by NMDA receptor activation.[13] Under basal conditions, the regulated pathway is essentially inactive, being transiently activated only upon the induction of long-term potentiation.[48][49] This pathway is responsible for synaptic strengthening and the initial formation of new memories.[51]

In the constitutive pathway, GluA1-lacking AMPA receptors, usually GluR2-GluR3 heteromeric receptors, replace the GluA1-containing receptors in a one-for-one, activity-independent manner,[52][53] preserving the total number of AMPA receptors in the synapse.[48][49] This pathway is responsible for the maintenance of new memories, sustaining the transient changes resulting from the regulated pathway. Under basal conditions, this pathway is routinely active, as it is necessary also for the replacement of damaged receptors.

The GluA1 and GluA4 subunits consist of a long carboxy (C)-tail, whereas the GluA2 and GluA3 subunits consist of a short carboxy-tail. The two pathways are governed by interactions between the C termini of the AMPA receptor subunits and synaptic compounds and proteins. Long C-tails prevent GluR1/4 receptors from being inserted directly into the postsynaptic density zone (PSDZ) in the absence of activity, whereas the short C-tails of GluA2/3 receptors allow them to be inserted directly into the PSDZ.[38][54] The GluA2 C terminus interacts with and binds to N-ethylmaleimide sensitive fusion protein,[55][56][57] which allows for the rapid insertion of GluR2-containing AMPA receptors at the synapse.[58] In addition, GluR2/3 subunits are more stably tethered to the synapse than GluR1 subunits.[59][60][61]

LTD-induced endocytosis of AMPA receptors[]

LTD-Induced AMPA Receptor Endocytosis
LTD-induced endocytosis of AMPA receptors

Long-term depression enacts mechanisms to decrease AMPA receptor density in selected dendritic spines, dependent on clathrin and calcineurin and distinct from that of constitutive AMPAR trafficking. The starting signal for AMPAR endocytosis is an NMDAR-dependent calcium influx from low-frequency stimulation, which in turn activates protein phosphatases PP1 and calcineurin. However, AMPAR endocytosis has also been activated by voltage-dependent calcium channels, agonism of AMPA receptors, and administration of insulin, suggesting general calcium influx as the cause of AMPAR endocytosis.[62] Blockage of PP1 did not prevent AMPAR endocytosis, but antagonist application to calcineurin led to significant inhibition of this process.[63]

Calcineurin interacts with an endocytotic complex at the postsynaptic zone, explaining its effects on LTD.[64] The complex, consisting of a clathrin-coated pit underneath a section of AMPAR-containing plasma membrane and interacting proteins, is the direct mechanism for reduction of AMPARs, in particular GluR2/GluR3 subunit-containing receptors, in the synapse. Interactions from calcineurin activate dynamin GTPase activity, allowing the clathrin pit to excise itself from the cell membrane and become a cytoplasmic vesicle.[65] Once the clathrin coat detaches, other proteins can interact directly with the AMPARs using PDZ carboxyl tail domains; for example, glutamate receptor-interacting protein 1 (GRIP1) has been implicated in intracellular sequestration of AMPARs.[66] Intracellular AMPARs are subsequently sorted for degradation by lysosomes or recycling to the cell membrane.[67] For the latter, PICK1 and PKC can displace GRIP1 to return AMPARs to the surface, reversing the effects of endocytosis and LTD. when appropriate.[68] Nevertheless, the highlighted calcium-dependent, dynamin-mediated mechanism above has been implicated as a key component of LTD. and as such may have applications to further behavioral research.[69]

Role in Seizures[]

AMPA receptors play a key role in the generation and spread of epileptic seizures.[70] Kainic acid, a convulsant that is widely used in epilepsy research induces seizures, in part, via activation of AMPA receptors[71]

Molecular target for epilepsy therapy[]

The noncompetitive AMPA receptor antagonists talampanel and perampanel have been demonstrated to have activity in the treatment of adults with partial seizures,[72][73] indicating that AMPA receptor antagonists represent a potential target for the treatment of epilepsy.[74] [75] Perampanel (trade name: Fycompa) received Marketing Authorisation Approval by the European Commission for the treatment of partial epilepsy on July 27, 2012. The drug was approved in the United States by the Food and Drug Administration (FDA) on October 22, 2012. As has been the case for most recently developed AEDs including pregabalin, lacosamide and ezogabine, the FDA recommended that perampanel be classified by the Drug Enforcement Administration (DEA) as a scheduled drug. It has been designated as a Schedule 3 controlled substance.

Decanoic acid acts as a non-competitive AMPA receptor antagonist at therapeutically relevant concentrations, in a voltage- and subunit-dependent manner, and this is sufficient to explain its antiseizure effects.[76] This direct inhibition of excitatory neurotransmission by decanoic acid in the brain contributes to the anticonvulsant effect of the medium-chain triglyceride ketogenic diet.[76] Decanoic acid and the AMPA receptor antagonist drug perampanel act at separate sites on the AMPA receptor, and so it is possible that they have a cooperative effect at the AMPA receptor, suggesting that perampanel and the ketogenic diet could be synergistic.[76]

Preclinical research suggest that several derivatives of aromatic amino acids with antiglutamatergic properties including AMPA receptor antagonism and inhibition of glutamate release such as 3,5-dibromo-D-tyrosine and 3,5-dibromo-L-phenylalnine exhibit strong anticonvulsant effect in animal models suggesting use of these compounds as a novel class of antiepileptic drugs.[77][78]

Agonists[]

Glutamate, the endogenous agonist of the AMPAR.
AMPA, a synthetic agonist of the AMPAR.
  • 5-Fluorowillardiine – a synthetic modification of willardiine
  • AMPA – a synthetic agonist after which the receptor is named
  • Domoic acid – a naturally occurring agonist that causes amnesic shellfish poisoning
  • Glutamic acid (glutamate) – the endogenous agonist
  • Ibotenic acid – a naturally occurring agonist found in Amanita muscaria
  • Quisqualic acid – a naturally occurring agonist found in certain species
  • Willardiine – a naturally occurring agonist

Positive allosteric modulators[]

Main article: AMPA receptor positive allosteric modulator

Antagonists[]

Negative allosteric modulators[]

Perampanel, a negative allosteric modulator of the AMPAR used to treat epilepsy.
  • Barbiturates (e.g., pentobarbital, sodium thiopental) – non-selective
  • Ethanol – non-selective
  • Inhalational anaesthetics (e.g., cyclopropane, enflurane, halothane, isoflurane, sevoflurane) – non-selective
  • GYKI-52466
  • Irampanel
  • Perampanel
  • Talampanel
  • PEP1-TGL : GluA1 subunit C-terminus peptide analog that inhibits AMPA receptor incorporation to the postsynaptic density[82][83]

See also[]

  • Arc/Arg3.1

References[]

  1. ^ Honoré T, Lauridsen J, Krogsgaard-Larsen P (January 1982). "The binding of [3H]AMPA, a structural analogue of glutamic acid, to rat brain membranes". Journal of Neurochemistry. 38 (1): 173���8. doi:10.1111/j.1471-4159.1982.tb10868.x. PMID 6125564. S2CID 42753770.
  2. ^ Armstrong N (2000). "Armstrong and Gouaux (2000) Mechanisms for Activation and Antagonism of an AMPA-Sensitive Glutamate Receptor: Crystal Structures of the GluR2 Ligand Binding Core". Neuron. 28 (1): 165–181. doi:10.1016/S0896-6273(00)00094-5. PMID 11086992. S2CID 3128719.
  3. ^ "Glutamate receptors: Structures and functions. University of Bristol Centre for Synaptic Plasticity". Archived from the original on 15 September 2007. Retrieved 2007-09-02.
  4. ^ Shi SH, Hayashi Y, Petralia RS, Zaman SH, Wenthold RJ, Svoboda K, Malinow R (June 1999). "Rapid spine delivery and redistribution of AMPA receptors after synaptic NMDA receptor activation". Science. 284 (5421): 1811–6. CiteSeerX 10.1.1.376.3281. doi:10.1126/science.284.5421.1811. PMID 10364548.
  5. ^ Song I, Huganir RL (November 2002). "Regulation of AMPA receptors during synaptic plasticity". Trends in Neurosciences. 25 (11): 578–88. doi:10.1016/S0166-2236(02)02270-1. PMID 12392933. S2CID 1993509.
  6. ^ a b Mayer ML (June 2005). "Glutamate receptor ion channels" (PDF). Current Opinion in Neurobiology. 15 (3): 282–8. doi:10.1016/j.conb.2005.05.004. PMID 15919192. S2CID 39812856.
  7. ^ a b Greger IH, Ziff EB, Penn AC (August 2007). "Molecular determinants of AMPA receptor subunit assembly". Trends in Neurosciences. 30 (8): 407–16. doi:10.1016/j.tins.2007.06.005. PMID 17629578. S2CID 7505830.
  8. ^ Hollmann M, Maron C, Heinemann S (December 1994). "N-glycosylation site tagging suggests a three transmembrane domain topology for the glutamate receptor GluR1". Neuron. 13 (6): 1331–43. doi:10.1016/0896-6273(94)90419-7. PMID 7993626. S2CID 39682094.
  9. ^ Leonard AS, Davare MA, Horne MC, Garner CC, Hell JW (July 1998). "SAP97 is associated with the alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor GluR1 subunit". The Journal of Biological Chemistry. 273 (31): 19518–24. doi:10.1074/jbc.273.31.19518. PMID 9677374.
  10. ^ a b Greger IH, Khatri L, Ziff EB (May 2002). "RNA editing at arg607 controls AMPA receptor exit from the endoplasmic reticulum". Neuron. 34 (5): 759–72. doi:10.1016/S0896-6273(02)00693-1. PMID 12062022. S2CID 15936250.
  11. ^ Bats C, Groc L, Choquet D (March 2007). "The interaction between Stargazin and PSD-95 regulates AMPA receptor surface trafficking". Neuron. 53 (5): 719–34. doi:10.1016/j.neuron.2007.01.030. PMID 17329211. S2CID 16423733.
  12. ^ Boehm J, Kang MG, Johnson RC, Esteban J, Huganir RL, Malinow R (July 2006). "Synaptic incorporation of AMPA receptors during LTP is controlled by a PKC phosphorylation site on GluR1". Neuron. 51 (2): 213–25. doi:10.1016/j.neuron.2006.06.013. PMID 16846856. S2CID 16208091.
  13. ^ a b Hayashi Y, Shi SH, Esteban JA, Piccini A, Poncer JC, Malinow R (March 2000). "Driving AMPA receptors into synapses by LTP and CaMKII: requirement for GluR1 and PDZ domain interaction". Science. 287 (5461): 2262–7. doi:10.1126/science.287.5461.2262. PMID 10731148. S2CID 17001488.
  14. ^ Derkach V, Barria A, Soderling TR (March 1999). "Ca2+/calmodulin-kinase II enhances channel conductance of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate type glutamate receptors". Proceedings of the National Academy of Sciences of the United States of America. 96 (6): 3269–74. doi:10.1073/pnas.96.6.3269. PMC 15931. PMID 10077673.
  15. ^ Delgado JY, Coba M, Anderson CN, Thompson KR, Gray EE, Heusner CL, et al. (November 2007). "NMDA receptor activation dephosphorylates AMPA receptor glutamate receptor 1 subunits at threonine 840". The Journal of Neuroscience. 27 (48): 13210–21. doi:10.1523/JNEUROSCI.3056-07.2007. PMC 2851143. PMID 18045915.
  16. ^ Banke TG, Bowie D, Lee H, Huganir RL, Schousboe A, Traynelis SF (January 2000). "Control of GluR1 AMPA receptor function by cAMP-dependent protein kinase". The Journal of Neuroscience. 20 (1): 89–102. doi:10.1523/JNEUROSCI.20-01-00089.2000. PMC 6774102. PMID 10627585.
  17. ^ Armstrong N, Sun Y, Chen GQ, Gouaux E (October 1998). "Structure of a glutamate-receptor ligand-binding core in complex with kainate". Nature. 395 (6705): 913–7. doi:10.1038/27692. PMID 9804426. S2CID 4405926.
  18. ^ a b Platt SR (March 2007). "The role of glutamate in central nervous system health and disease--a review". Veterinary Journal. 173 (2): 278–86. doi:10.1016/j.tvjl.2005.11.007. PMID 16376594.
  19. ^ Rosenmund C, Stern-Bach Y, Stevens CF (June 1998). "The tetrameric structure of a glutamate receptor channel". Science. 280 (5369): 1596–9. doi:10.1126/science.280.5369.1596. hdl:11858/00-001M-0000-0012-FDD8-B. PMID 9616121.
  20. ^ Armstrong N, Jasti J, Beich-Frandsen M, Gouaux E (October 2006). "Measurement of conformational changes accompanying desensitization in an ionotropic glutamate receptor". Cell. 127 (1): 85–97. doi:10.1016/j.cell.2006.08.037. PMID 17018279. S2CID 16564029.
  21. ^ Kim DY, Kim SH, Choi HB, Min C, Gwag BJ (June 2001). "High abundance of GluR1 mRNA and reduced Q/R editing of GluR2 mRNA in individual NADPH-diaphorase neurons". Molecular and Cellular Neurosciences. 17 (6): 1025–33. doi:10.1006/mcne.2001.0988. PMID 11414791. S2CID 15351461.
  22. ^ Lüscher C, Malenka RC (February 2011). "Drug-evoked synaptic plasticity in addiction: from molecular changes to circuit remodeling". Neuron. 69 (4): 650–63. doi:10.1016/j.neuron.2011.01.017. PMC 4046255. PMID 21338877.
  23. ^ Herbrechter R, Hube N, Buchholz R, Reiner A (July 2021). "Splicing and editing of ionotropic glutamate receptors: a comprehensive analysis based on human RNA-Seq data". Cellular and Molecular Life Sciences. 78 (14): 5605–5630. doi:10.1007/s00018-021-03865-z. PMC 8257547. PMID 34100982.
  24. ^ Mosbacher J, Schoepfer R, Monyer H, Burnashev N, Seeburg PH, Ruppersberg JP (November 1994). "A molecular determinant for submillisecond desensitization in glutamate receptors". Science. 266 (5187): 1059–62. doi:10.1126/science.7973663. PMID 7973663.
  25. ^ Sommer B, Keinänen K, Verdoorn TA, Wisden W, Burnashev N, Herb A, et al. (September 1990). "Flip and flop: a cell-specific functional switch in glutamate-operated channels of the CNS". Science. 249 (4976): 1580–5. doi:10.1126/science.1699275. PMID 1699275.
  26. ^ Pei W, Huang Z, Niu L (February 2007). "GluR3 flip and flop: differences in channel opening kinetics". Biochemistry. 46 (7): 2027–36. doi:10.1021/bi062213s. PMID 17256974.
  27. ^ Eastwood SL, Burnet PW, Harrison PJ (February 1997). "GluR2 glutamate receptor subunit flip and flop isoforms are decreased in the hippocampal formation in schizophrenia: a reverse transcriptase-polymerase chain reaction (RT-PCR) study". Brain Research. Molecular Brain Research. 44 (1): 92–8. doi:10.1016/s0169-328x(96)00195-7. PMID 9030702.
  28. ^ Whitlock JR, Heynen AJ, Shuler MG, Bear MF (August 2006). "Learning induces long-term potentiation in the hippocampus". Science. 313 (5790): 1093–7. doi:10.1126/science.1128134. PMID 16931756. S2CID 612352.
  29. ^ Maren S, Tocco G, Standley S, Baudry M, Thompson RF (October 1993). "Postsynaptic factors in the expression of long-term potentiation (LTP): increased glutamate receptor binding following LTP induction in vivo". Proceedings of the National Academy of Sciences of the United States of America. 90 (20): 9654–8. doi:10.1073/pnas.90.20.9654. PMC 47628. PMID 8415757.
  30. ^ Perkinton MS, Sihra TS, Williams RJ (July 1999). "Ca(2+)-permeable AMPA receptors induce phosphorylation of cAMP response element-binding protein through a phosphatidylinositol 3-kinase-dependent stimulation of the mitogen-activated protein kinase signaling cascade in neurons". The Journal of Neuroscience. 19 (14): 5861–74. doi:10.1523/JNEUROSCI.19-14-05861.1999. PMC 6783096. PMID 10407026.
  31. ^ Fukunaga K, Stoppini L, Miyamoto E, Muller D (April 1993). "Long-term potentiation is associated with an increased activity of Ca2+/calmodulin-dependent protein kinase II". The Journal of Biological Chemistry. 268 (11): 7863–7. doi:10.1016/S0021-9258(18)53037-4. PMID 8385124.
  32. ^ Lisman J, Schulman H, Cline H (March 2002). "The molecular basis of CaMKII function in synaptic and behavioural memory". Nature Reviews. Neuroscience. 3 (3): 175–90. doi:10.1038/nrn753. PMID 11994750. S2CID 5844720.
  33. ^ Mammen AL, Kameyama K, Roche KW, Huganir RL (December 1997). "Phosphorylation of the alpha-amino-3-hydroxy-5-methylisoxazole4-propionic acid receptor GluR1 subunit by calcium/calmodulin-dependent kinase II". The Journal of Biological Chemistry. 272 (51): 32528–33. doi:10.1074/jbc.272.51.32528. PMID 9405465.
  34. ^ Ebert DH, Greenberg ME (January 2013). "Activity-dependent neuronal signalling and autism spectrum disorder". Nature. 493 (7432): 327–37. doi:10.1038/nature11860. PMC 3576027. PMID 23325215.
  35. ^ Mauceri D, Cattabeni F, Di Luca M, Gardoni F (May 2004). "Calcium/calmodulin-dependent protein kinase II phosphorylation drives synapse-associated protein 97 into spines". The Journal of Biological Chemistry. 279 (22): 23813–21. doi:10.1074/jbc.M402796200. PMID 15044483.
  36. ^ Wu H, Nash JE, Zamorano P, Garner CC (August 2002). "Interaction of SAP97 with minus-end-directed actin motor myosin VI. Implications for AMPA receptor trafficking". The Journal of Biological Chemistry. 277 (34): 30928–34. doi:10.1074/jbc.M203735200. PMID 12050163.
  37. ^ Zhu JJ, Qin Y, Zhao M, Van Aelst L, Malinow R (August 2002). "Ras and Rap control AMPA receptor trafficking during synaptic plasticity". Cell. 110 (4): 443–55. doi:10.1016/S0092-8674(02)00897-8. PMID 12202034. S2CID 12858091.
  38. ^ a b Borgdorff AJ, Choquet D (June 2002). "Regulation of AMPA receptor lateral movements". Nature. 417 (6889): 649–53. doi:10.1038/nature00780. PMID 12050666. S2CID 4422115.
  39. ^ Park M, Penick EC, Edwards JG, Kauer JA, Ehlers MD (September 2004). "Recycling endosomes supply AMPA receptors for LTP". Science. 305 (5692): 1972–5. doi:10.1126/science.1102026. PMID 15448273. S2CID 34651431.
  40. ^ Makino H, Malinow R (November 2009). "AMPA receptor incorporation into synapses during LTP: the role of lateral movement and exocytosis". Neuron. 64 (3): 381–90. doi:10.1016/j.neuron.2009.08.035. PMC 2999463. PMID 19914186.
  41. ^ Howard MA, Elias GM, Elias LA, Swat W, Nicoll RA (February 2010). "The role of SAP97 in synaptic glutamate receptor dynamics". Proceedings of the National Academy of Sciences of the United States of America. 107 (8): 3805–10. doi:10.1073/pnas.0914422107. PMC 2840522. PMID 20133708.
  42. ^ Waites CL, Specht CG, Härtel K, Leal-Ortiz S, Genoux D, Li D, et al. (April 2009). "Synaptic SAP97 isoforms regulate AMPA receptor dynamics and access to presynaptic glutamate". The Journal of Neuroscience. 29 (14): 4332–45. doi:10.1523/JNEUROSCI.4431-08.2009. PMC 3230533. PMID 19357261.
  43. ^ Wang Z, Edwards JG, Riley N, Provance DW, Karcher R, Li XD, et al. (October 2008). "Myosin Vb mobilizes recycling endosomes and AMPA receptors for postsynaptic plasticity". Cell. 135 (3): 535–48. doi:10.1016/j.cell.2008.09.057. PMC 2585749. PMID 18984164.
  44. ^ Nicoll RA, Tomita S, Bredt DS (March 2006). "Auxiliary subunits assist AMPA-type glutamate receptors". Science. 311 (5765): 1253–6. doi:10.1126/science.1123339. PMID 16513974. S2CID 40782882.
  45. ^ Tomita S, Chen L, Kawasaki Y, Petralia RS, Wenthold RJ, Nicoll RA, Bredt DS (May 2003). "Functional studies and distribution define a family of transmembrane AMPA receptor regulatory proteins". The Journal of Cell Biology. 161 (4): 805–16. doi:10.1083/jcb.200212116. PMC 2199354. PMID 12771129.
  46. ^ Chen L, Chetkovich DM, Petralia RS, Sweeney NT, Kawasaki Y, Wenthold RJ, et al. (2000). "Stargazin regulates synaptic targeting of AMPA receptors by two distinct mechanisms". Nature. 408 (6815): 936–43. doi:10.1038/35050030. PMID 11140673. S2CID 4427689.
  47. ^ Bats C, Groc L, Choquet D (March 2007). "The interaction between Stargazin and PSD-95 regulates AMPA receptor surface trafficking". Neuron. 53 (5): 719–34. doi:10.1016/j.neuron.2007.01.030. PMID 17329211. S2CID 16423733.
  48. ^ a b c Shepherd JD, Huganir RL (2007). "The cell biology of synaptic plasticity: AMPA receptor trafficking". Annual Review of Cell and Developmental Biology. 23: 613–43. doi:10.1146/annurev.cellbio.23.090506.123516. PMID 17506699. S2CID 7048661.
  49. ^ a b c Malinow R, Mainen ZF, Hayashi Y (June 2000). "LTP mechanisms: from silence to four-lane traffic". Current Opinion in Neurobiology. 10 (3): 352–7. doi:10.1016/S0959-4388(00)00099-4. PMID 10851179. S2CID 511079.
  50. ^ Malenka RC (November 2003). "Synaptic plasticity and AMPA receptor trafficking". Annals of the New York Academy of Sciences. 1003: 1–11. doi:10.1196/annals.1300.001. PMID 14684431. S2CID 22696062.
  51. ^ Kessels HW, Malinow R (February 2009). "Synaptic AMPA receptor plasticity and behavior". Neuron. 61 (3): 340–50. doi:10.1016/j.neuron.2009.01.015. PMC 3917551. PMID 19217372.
  52. ^ McCormack SG, Stornetta RL, Zhu JJ (April 2006). "Synaptic AMPA receptor exchange maintains bidirectional plasticity". Neuron. 50 (1): 75–88. doi:10.1016/j.neuron.2006.02.027. PMID 16600857. S2CID 17478776.
  53. ^ Zhu JJ, Esteban JA, Hayashi Y, Malinow R (November 2000). "Postnatal synaptic potentiation: delivery of GluR4-containing AMPA receptors by spontaneous activity". Nature Neuroscience. 3 (11): 1098–106. doi:10.1038/80614. hdl:10261/47079. PMID 11036266. S2CID 16116261.
  54. ^ Passafaro M, Piëch V, Sheng M (September 2001). "Subunit-specific temporal and spatial patterns of AMPA receptor exocytosis in hippocampal neurons". Nature Neuroscience. 4 (9): 917–26. doi:10.1038/nn0901-917. PMID 11528423. S2CID 32852272.
  55. ^ Song I, Kamboj S, Xia J, Dong H, Liao D, Huganir RL (August 1998). "Interaction of the N-ethylmaleimide-sensitive factor with AMPA receptors". Neuron. 21 (2): 393–400. doi:10.1016/S0896-6273(00)80548-6. PMID 9728920.
  56. ^ Osten P, Srivastava S, Inman GJ, Vilim FS, Khatri L, Lee LM, et al. (July 1998). "The AMPA receptor GluR2 C terminus can mediate a reversible, ATP-dependent interaction with NSF and alpha- and beta-SNAPs". Neuron. 21 (1): 99–110. doi:10.1016/S0896-6273(00)80518-8. PMID 9697855. S2CID 18569829.
  57. ^ Nishimune A, Isaac JT, Molnar E, Noel J, Nash SR, Tagaya M, et al. (July 1998). "NSF binding to GluR2 regulates synaptic transmission". Neuron. 21 (1): 87–97. doi:10.1016/S0896-6273(00)80517-6. hdl:2433/180867. PMID 9697854. S2CID 18956893.
  58. ^ Beretta F, Sala C, Saglietti L, Hirling H, Sheng M, Passafaro M (April 2005). "NSF interaction is important for direct insertion of GluR2 at synaptic sites". Molecular and Cellular Neurosciences. 28 (4): 650–60. doi:10.1016/j.mcn.2004.11.008. PMID 15797712. S2CID 46716417.
  59. ^ Cingolani LA, Thalhammer A, Yu LM, Catalano M, Ramos T, Colicos MA, Goda Y (June 2008). "Activity-dependent regulation of synaptic AMPA receptor composition and abundance by beta3 integrins". Neuron. 58 (5): 749–62. doi:10.1016/j.neuron.2008.04.011. PMC 2446609. PMID 18549786.
  60. ^ Saglietti L, Dequidt C, Kamieniarz K, Rousset MC, Valnegri P, Thoumine O, et al. (May 2007). "Extracellular interactions between GluR2 and N-cadherin in spine regulation". Neuron. 54 (3): 461–77. doi:10.1016/j.neuron.2007.04.012. PMID 17481398. S2CID 14600986.
  61. ^ Silverman JB, Restituito S, Lu W, Lee-Edwards L, Khatri L, Ziff EB (August 2007). "Synaptic anchorage of AMPA receptors by cadherins through neural plakophilin-related arm protein AMPA receptor-binding protein complexes". The Journal of Neuroscience. 27 (32): 8505–16. doi:10.1523/JNEUROSCI.1395-07.2007. PMC 6672939. PMID 17687028.
  62. ^ Carroll RC, Beattie EC, Xia H, Lüscher C, Altschuler Y, Nicoll RA, et al. (November 1999). "Dynamin-dependent endocytosis of ionotropic glutamate receptors". Proceedings of the National Academy of Sciences of the United States of America. 96 (24): 14112–7. doi:10.1073/pnas.96.24.14112. PMC 24199. PMID 10570207.
  63. ^ Beattie EC, Carroll RC, Yu X, Morishita W, Yasuda H, von Zastrow M, Malenka RC (December 2000). "Regulation of AMPA receptor endocytosis by a signaling mechanism shared with LTD". Nature Neuroscience. 3 (12): 1291–300. doi:10.1038/81823. PMID 11100150.
  64. ^ Lai MM, Hong JJ, Ruggiero AM, Burnett PE, Slepnev VI, De Camilli P, Snyder SH (September 1999). "The calcineurin-dynamin 1 complex as a calcium sensor for synaptic vesicle endocytosis". The Journal of Biological Chemistry. 274 (37): 25963–6. doi:10.1074/jbc.274.37.25963. PMID 10473536.
  65. ^ Jung N, Haucke V (September 2007). "Clathrin-mediated endocytosis at synapses". Traffic. 8 (9): 1129–36. doi:10.1111/j.1600-0854.2007.00595.x. PMID 17547698.
  66. ^ Daw MI, Chittajallu R, Bortolotto ZA, Dev KK, Duprat F, Henley JM, et al. (December 2000). "PDZ proteins interacting with C-terminal GluR2/3 are involved in a PKC-dependent regulation of AMPA receptors at hippocampal synapses". Neuron. 28 (3): 873–86. doi:10.1016/S0896-6273(00)00160-4. hdl:2262/89240. PMID 11163273. S2CID 13727678.
  67. ^ Ehlers MD (November 2000). "Reinsertion or degradation of AMPA receptors determined by activity-dependent endocytic sorting". Neuron. 28 (2): 511–25. doi:10.1016/S0896-6273(00)00129-X. PMID 11144360. S2CID 16333109.
  68. ^ Lu W, Ziff EB (August 2005). "PICK1 interacts with ABP/GRIP to regulate AMPA receptor trafficking". Neuron. 47 (3): 407–21. doi:10.1016/j.neuron.2005.07.006. PMID 16055064. S2CID 17100359.
  69. ^ Wang YT (March 2008). "Probing the role of AMPAR endocytosis and long-term depression in behavioural sensitization: relevance to treatment of brain disorders, including drug addiction". British Journal of Pharmacology. 153 Suppl 1 (S1): S389-95. doi:10.1038/sj.bjp.0707616. PMC 2268058. PMID 18059315.
  70. ^ Rogawski MA (2013). "AMPA receptors as a molecular target in epilepsy therapy". Acta Neurologica Scandinavica. Supplementum. 127 (197): 9–18. doi:10.1111/ane.12099. PMC 4506648. PMID 23480151.
  71. ^ Fritsch B, Reis J, Gasior M, Kaminski RM, Rogawski MA (April 2014). "Role of GluK1 kainate receptors in seizures, epileptic discharges, and epileptogenesis". The Journal of Neuroscience. 34 (17): 5765–75. doi:10.1523/JNEUROSCI.5307-13.2014. PMC 3996208. PMID 24760837.
  72. ^ Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Perucca E, Tomson T (January 2007). "Progress report on new antiepileptic drugs: a summary of the Eighth Eilat Conference (EILAT VIII)". Epilepsy Research. 73 (1): 1–52. doi:10.1016/j.eplepsyres.2006.10.008. PMID 17158031. S2CID 45026113.
  73. ^ French JA, Krauss GL, Biton V, Squillacote D, Yang H, Laurenza A, et al. (August 2012). "Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304". Neurology. 79 (6): 589–96. doi:10.1212/WNL.0b013e3182635735. PMC 3413761. PMID 22843280.
  74. ^ Rogawski MA (March 2011). "Revisiting AMPA receptors as an antiepileptic drug target". Epilepsy Currents. 11 (2): 56–63. doi:10.5698/1535-7511-11.2.56. PMC 3117497. PMID 21686307.
  75. ^ Sakai F, Igarashi H, Suzuki S, Tazaki Y (1989). "Cerebral blood flow and cerebral hematocrit in patients with cerebral ischemia measured by single-photon emission computed tomography". Acta Neurologica Scandinavica. Supplementum. 127: 9–13. doi:10.1111/j.1600-0404.1989.tb01805.x. PMID 2631521. S2CID 30934688.
  76. ^ a b c Chang P, Augustin K, Boddum K, Williams S, Sun M, Terschak JA, et al. (February 2016). "Seizure control by decanoic acid through direct AMPA receptor inhibition". Brain. 139 (Pt 2): 431–43. doi:10.1093/brain/awv325. PMC 4805082. PMID 26608744.
  77. ^ Cao W, Shah HP, Glushakov AV, Mecca AP, Shi P, Sumners C, et al. (December 2009). "Efficacy of 3,5-dibromo-L-phenylalanine in rat models of stroke, seizures and sensorimotor gating deficit". British Journal of Pharmacology. 158 (8): 2005–13. doi:10.1111/j.1476-5381.2009.00498.x. PMC 2807662. PMID 20050189.
  78. ^ Cao W, Glushakov A, Shah HP, Mecca AP, Sumners C, Shi P, et al. (April 2011). "Halogenated aromatic amino acid 3,5-dibromo-D: -tyrosine produces beneficial effects in experimental stroke and seizures". Amino Acids. 40 (4): 1151–8. doi:10.1007/s00726-010-0739-4. PMC 8396070. PMID 20839013. S2CID 19852158.
  79. ^ Murray TK, Whalley K, Robinson CS, Ward MA, Hicks CA, Lodge D, et al. (August 2003). "LY503430, a novel alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor potentiator with functional, neuroprotective and neurotrophic effects in rodent models of Parkinson's disease". The Journal of Pharmacology and Experimental Therapeutics. 306 (2): 752–62. doi:10.1124/jpet.103.049445. PMID 12730350. S2CID 86751458.
  80. ^ O'Neill MJ, Bleakman D, Zimmerman DM, Nisenbaum ES (June 2004). "AMPA receptor potentiators for the treatment of CNS disorders". Current Drug Targets. CNS and Neurological Disorders. 3 (3): 181–94. doi:10.2174/1568007043337508. PMID 15180479.
  81. ^ Yarotskyy V, Glushakov AV, Sumners C, Gravenstein N, Dennis DM, Seubert CN, Martynyuk AE (May 2005). "Differential modulation of glutamatergic transmission by 3,5-dibromo-L-phenylalanine". Molecular Pharmacology. 67 (5): 1648–54. doi:10.1124/mol.104.005983. PMID 15687225. S2CID 11672391.
  82. ^ Hayashi, Yasunori; Shi, Song-Hai; Esteban, José A.; Piccini, Antonella; Poncer, Jean-Christophe; Malinow, Roberto (24 March 2000). "Hayashi et al (200) Driving AMPA Receptors into Synapses by LTP and CaMKII: Requirement for GluR1 and PDZ Domain Interaction. Science 287; 2262-2267". Science. 287 (5461): 2262–2267. doi:10.1126/science.287.5461.2262. PMID 10731148.
  83. ^ Tazerart S, Mitchell DE, Miranda-Rottmann S, Araya R (August 2020). "A spike-timing-dependent plasticity rule for dendritic spines". Nature Communications. 11 (1): 4276. doi:10.1038/s41467-020-17861-7. PMC 7449969. PMID 32848151.

External links[]

Retrieved from ""